Regular Article
Loss of Heterozygosity at 3p in Benign Lesions Preceding Invasive Breast Cancer

Presented at the Annual Meeting of the Association for Academic Surgery, Seattle, Washington, November 18–22, 1998
https://doi.org/10.1006/jsre.1998.5549Get rights and content

Abstract

Background.Loss of heterozygosity (LOH) at chromosome 3p is one of the most common genetic abnormalities identified in human cancers and has occasionally been noted in benign proliferative lesions predisposing to breast cancer. If the frequency of LOH at 3p in benign proliferative lesions correlates with the subsequent development of breast cancer, it may be possible to develop powerful tools for molecular risk assessment based on this technology.

Materials and methods.Archival paraffin-embedded tissues from benign breast biopsies in five women who have developed breast cancer and three women who have not developed breast cancer were microdissected and allelotyped at 3p using six microsatellite markers.

Results.No LOH was detected in the biopsies from women who have not developed breast cancer. For women developing breast cancer, the proportion of informative loci showing LOH in the benign proliferative lesions was 0.47 as compared to 0.57 for the associated breast cancers. There was no LOH detected in epithelial DNA from a fibroadenoma. Of 15 informative loci, 4 (27%) showed LOH in both the benign proliferative lesion and the associated cancer; however, the actual parental allele lost was different in three of these four cases.

Conclusions.These results suggest that there are specific patterns of genetic instability common to preneoplastic lesions and the breast cancers that subsequently develop even when the paired lesions are not clonally related. LOH analysis of benign breast epithelium may provide a tool for molecular risk assessment and a surrogate endpoint for breast cancer chemoprevention trials.

References (26)

  • G. Eiriksdottir et al.

    High incidence of loss of heterozygosity at chromosome 17p13 in breast tumors from BRCA2 mutation carriers

    Oncogene

    (1998)
  • B. Tedeschi et al.

    Population cytogenetics of aphidicholin-induced fragile sites

    Hum. Genet.

    (1992)
  • Cited by (19)

    View all citing articles on Scopus
    1

    To whom correspondence should be addressed at Division of Surgical Oncology E6.222, U.T. Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9155.

    View full text